Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Business Wire
First regulatory approval of an OmniAb-derived antibody EMERYVILLE, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China’s National Medical Products Administration (NMPA) for zimberelimab (GLS-010), an OmniAb-derived anti-PD-1 monoclonal antibody for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL). GloriaBio has development and commercialization rights in China with respect to zimberelimab through a sublicense agreement with Ligand's licensee Wuxi Biologics Ireland Limited.Zimberelimab is a fully human monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors. It is designed to bind to PD-1, a cell surface receptor that plays an important role in the downregulation of the immune system by preventing the activation of T cells. Other anti-PD-1 antibodies have been approved by the U.S. FDA
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $95.00 price target on the stock.MarketBeat
- CDK9 inhibitor Drug Pipeline Research Report 2024 [Yahoo! Finance]Yahoo! Finance
- Can Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Performance Keep Up Given Its Mixed Bag Of Fundamentals? [Yahoo! Finance]Yahoo! Finance
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference [Yahoo! Finance]Yahoo! Finance
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures ConferenceBusiness Wire
LGND
Earnings
- 2/27/24 - Beat
LGND
Sec Filings
- 4/19/24 - Form 8-K
- 3/27/24 - Form 4
- 3/7/24 - Form 4
- LGND's page on the SEC website